EUVIMEDObjevte EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

Prevalence and Characteristics of Potential QT ‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs

Fatimah Alhurayri, Islam R Younis iD, Shadia I Jalal iD, Theodore F Logan iD, Rohan Maniar iD, Steven M Bray iD, Sara K Quinney iD, Zeruesenay Desta iD, Todd C Skaar iD, James E Tisdale iD, Tyler Shugg iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-12 · 46 (12)

DOI: 10.1002/phar.70217 ↗

At a glance

Beobachtungsstudie in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2026-11-15. Written by Fatimah Alhurayri and 10 co-authors. Institution: Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, Indiana, USA. Major MEDLINE topics: Antineoplastic Agents, Long QT Syndrome, Neoplasms. 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Patients with cancer are at increased risk of QT interval prolongation because of polypharmacy and concomitant use of QT‐prolonging medications. Drug–drug interactions (DDIs) may further increase this risk. Outpatient electrocardiogram (ECG) monitoring appears to be underused among patients receiving oral anticancer drugs (OADs). Our study objective was to evaluate the prevalence and characteristics of potential QT interval–prolonging drug–drug interactions (QT pDDIs) in patients with cancer receiving OAD therapy.

Methods

A retrospective observational study was conducted using electronic health record data from 3697 patients with advanced cancer. Patients who received at least one OAD were included in the analysis. Potential QT‐related DDIs were identified through overlap prescriptions of concomitant medications associated with QT prolongation and/or Cytochrome P450‐ (CYP‐) or drug transporter‐mediated interactions during OAD exposure. Descriptive analyses were performed to characterize the prevalence and types of QT pDDIs.

Results

Of the 3697 patients, 1732 (46.8%) received at least one OAD and were included in the analysis. Of these, 17.1% experienced at least one QT pDDI. Among those patients, 47.5% experienced PD‐QT pDDIs only, 21.2% experienced PK‐QT pDDIs only, and 31.3% experienced both PD‐ and PK‐QT pDDIs during OAD exposure. Concurrent PD and PK mechanisms occurred simultaneously in 30.6% of patients with QT‐pDDIs. Approximately 48% of identified QT pDDIs involved at least one OAD, most commonly pazopanib (13.5%), palbociclib (11.3%), and vandetanib (8.4%).

Conclusion

QT pDDIs were common among patients with cancer receiving OADs, highlighting the importance of comprehensive DDI screening, careful medication review, and enhanced cardiac monitoring strategies in oncology practice.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsLong QT SyndromeNeoplasmsHumansDrug InteractionsFemaleRetrospective StudiesMalePrevalenceAdministration, OralElectrocardiographyAgedMiddle AgedAged, 80 and over

Author keywords

QT prolongationdrug–drug interactionsoral anticancer drugspharmacodynamicspharmacokinetics

Substances

Antineoplastic Agents

Authors and institutions

  • Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, Indiana, USA.
  • College of Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Department of Quantitative Pharmacology & Pharmacometrics, Merck & Co., Rahway, New Jersey, USA.
  • Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Fountain Life, Inc., Indianapolis, Indiana, USA.
  • Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID profiles: Islam R Younis, Shadia I Jalal, Theodore F Logan, Rohan Maniar, Steven M Bray, Sara K Quinney, Zeruesenay Desta, Todd C Skaar, James E Tisdale, Tyler Shugg

Funding

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Cite

APA

Alhurayri, F., Younis, I. R., Jalal, S. I., Logan, T. F., Maniar, R., Bray, S. M., Quinney, S. K., Desta, Z., Skaar, T. C., Tisdale, J. E., & Shugg, T. (2026). Prevalence and Characteristics of Potential QT ‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(12). https://doi.org/10.1002/phar.70217

Vancouver

Alhurayri F, Younis IR, Jalal SI, Logan TF, Maniar R, Bray SM, et al. Prevalence and Characteristics of Potential QT ‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(12). doi:10.1002/phar.70217

BibTeX
@article{Alhurayri2026,
  author = {Alhurayri, Fatimah and Younis, Islam R and Jalal, Shadia I and Logan, Theodore F and Maniar, Rohan and Bray, Steven M and Quinney, Sara K and Desta, Zeruesenay and Skaar, Todd C and Tisdale, James E and Shugg, Tyler},
  title = {Prevalence and Characteristics of Potential QT ‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {12},
  doi = {10.1002/phar.70217}
}
Start for free →